**Summary of Convatec FY25 Results**
Convatec Group PLC reported strong financial results for the year ended December 31, 2025, with key highlights including
1. **Revenue Growth**Reported revenue increased by 6.5% to $2,439 million, driven by broad-based organic growth across all categories, geographies, and products. Organic revenue growth excluding InnovaMatrix® was 6.4%.
2. **Margin Improvement**Adjusted operating margin expanded by 110 basis points to 22.3%, despite challenges like a $30 million reduction in InnovaMatrix® sales and incremental tariffs. This improvement was fueled by operational efficiencies, pricing strategies, and operational leverage.
3. **Earnings Growth**Adjusted diluted EPS grew by 16.0% to 17.6 cents, reflecting strong operational performance and margin expansion.
4. **Cash Generation**Free cash flow to equity was $362 million, supporting investments in growth, dividends, and share buybacks. The company returned $300 million to shareholders via share repurchases.
5. **Dividend Increase**The final dividend for 2025 was increased by 13% to 5.367 cents per share, bringing the full-year dividend to 7.244 cents per share.
6. **Strategic Investments**Convatec invested $185 million in capital expenditures, focusing on capacity expansion, new product development, and automation to meet rising demand.
7. **Product Innovations**Key product launches and innovations, such as ConvaFoamTM, Esteem BodyTM, and GentleCath AirTM, drove growth and market share gains across categories.
8. **Medium-Term Outlook**Convatec upgraded its medium-term organic revenue growth target to 6-8% from 2027, supported by a rich innovation pipeline and successful strategy implementation.
9. **Financial Position**The company secured investment-grade status, extended its financing maturity, and maintained a strong balance sheet with net debt of $1,330 million, equivalent to 2.0x adjusted EBITDA.
10. **Future Prospects**Convatec expects double-digit adjusted EPS growth in FY26, with organic revenue growth of 5-7% excluding InnovaMatrix®, and continued margin expansion to at least 23.0%.
Overall, Convatecs FY25 results demonstrate resilient growth, strategic execution, and a strong foundation for future performance, underpinned by innovation, operational excellence, and disciplined capital allocation.